恩替卡韦对HBeAg阴性慢性乙型肝炎患者血清脂联素浓度的影响

Changes of the serum adiponectin during Entecavir therapy in patients with HBeAg negative chronic hepatitis B

目的观察HBeAg阴性慢性乙型肝炎患者恩替卡韦治疗前后血清脂联素水平的变化,探讨脂联素和HBeAg阴性慢性乙型肝炎之间的关系。方法 60例HBeAg阴性CHB患者接受恩替卡韦治疗24周,治疗前后采用ELISA法检测血清脂联素水平,同时检测肝功能、血脂、空腹血糖、HBV DNA载量,测量人体身高,体质量,计算体质指数(BMI)。结果 CHB患者使用恩替卡韦治疗24周后,ALT、AST、TBil、HBV DNA和脂联素水平较治疗前相比明显下降,差异有统计学意义(P<0.05),但TC、TO、BMI和FBG水平较治疗前相比差异无统计学意义(P>0.05)。结论HBeAg阴性慢性乙型肝炎患者血清脂联素水平与肝脏炎症活动相关,对于HBeAg阴性慢性乙型肝炎患者的抗病毒治疗效果以及预后的判断具有一定参考意义。

Objective To observe serum adiponectin levels in patients with HBeAg negative chronic hepatitis B （CHB）during entecavir therapy,and to investigate the relationship between serum adiponectin level and HBeAg negative CHB.Methods Sixty patients with HBeAg negative CHB were enrolled in this study and were assigned to entecavir therapy for 24 weeks.Serum adiponectin levels were detected by enzyme-linked immunosorbent assay （ELISA）before and after entecavir therapy.At the same time,liver function,blood lipid,fasting serum blood glucose （FBG）and HBV DNA load were also detected,respectively.After measurement of the height and body weight,body mass index （BMI）was calculated.Results Compared with those before entecavir therapy levels of ALT,AST,TBIL,HBV DNA and adiponectin decreased markedly after entecavir therapy （P 0.05）.Conclusion Adiponectin levels in patients with HBeAg negative CHB are correlated with liver inflammation activity,and have practical reference value for effective and prognosis of antiviral therapy.